All In Biotech

Drug Trial Radar · NCT04871919

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,304

Actual

Start

May 11, 2021

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Alfasigma S.p.A.Industry
Sponsor type
Industry
First posted
May 4, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.

Conditions

  • Rheumatoid Arthritis

Interventions

  • FilgotinibDrug

    Tablets are administered in accordance with the product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment persistence ratesTime frame: Up to 24 months

Locations

89 sites in 6 countries. Site status is shown where the registry gives one.

  • Algemeen Stedelijk Ziekenhuis

    Aalst, Belgium

  • Imelda VZW

    Bonheiden, Belgium

  • AZ Sint-Jan Brugge-Oostende

    Bruges, Belgium

  • Hôpital Erasme

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Grand Hôpital de Charleroi asbl

    Charleroi, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • Reumacentrum Genk

    Genk, Belgium

  • Reumaclinic Genk

    Genk, Belgium

  • AZ Maria Middelares

    Ghent, Belgium

  • Reuma Instituut

    Hasselt, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHU de Liège

    Liège, Belgium

  • ZNA Jan Palfijn

    Merksem, Belgium

  • CHU UCL Namur asbl - Site Godinne

    Yvoir, Belgium

  • Rheumazentrum Kupka

    Altenburg, Germany

  • Praxis für Rheumatologie - Amberg

    Amberg, Germany

  • Rheumatology Center Prof. Neeck

    Bad Doberan, Germany

  • Charité Campus Mitte, Klinik für Rheumatologie und Klinische Immunologie

    Berlin, Germany

  • Rheumatologische Schwerpunktpraxis

    Berlin, Germany

  • Rheumapraxis am Schlachtensee

    Berlin, Germany

  • Rheumapraxis Mexikoplatz

    Berlin, Germany

  • Klinik fur Innere Medizin - Rheumatologie - Kreiskrankenhaus Demmin

    Demmin, Germany

  • Rheumatologisches MVZ Dresden

    Dresden, Germany

  • Universitatsklinikum Dusseldorf

    Düsseldorf, Germany

  • Praxis Dilltal

    Ehringshausen, Germany

  • MVZ Ambulantes Rheumazentrum Erfurt

    Erfurt, Germany

  • Universitätsmedizin Greifswald, Abteilung Innere Medizin A

    Greifswald, Germany

  • Internistisch-Rheumatologische Arztpraxis

    Halle, Germany

  • Rheumatologie im Struenseehaus

    Hamburg, Germany

  • Praxis für Rheumatologie

    Hamburg, Germany

  • Rheumazentrum Ruhrgebiet

    Herne, Germany

  • Rheumapraxis

    Leipzig, Germany

  • Praxis für Internistische Rheumatologie

    Leipzig, Germany

  • Rheumatologische Facharztpraxis

    Magdeburg, Germany

  • Rheumapraxis

    Mansfeld, Germany

  • Praxis far Rheumatologie, Gastroenterologie und Innere Medizin

    München, Germany

  • Rheumatologisches Praxiszentrum St. Bonifatius

    München, Germany

  • Rheumapraxis

    Neubrandenburg, Germany

  • Medizinischen Versorgungszentrums für Rheumatologie

    Planegg, Germany

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.